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SURVIVOR HEALTH AND IMMUNE RECONSTITUTION IN THE SECOND
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The growing numbers of allogeneic hematopoietic stem cell trans-
plant (HSCT) survivors deserve a study of late effects. We analyzed
48 long term (range 10-16 years) survivors who underwent alloge-
neic HSCT at the NIH between 1993 and 2000. Their median age
at HSCTwas 35 years and the current median age is 49 years. There
were 20 males and 28 females. Forty-two patients received high dose
total body irradiation while the rest received reduced intensity con-
ditioning. Underlying diagnoses were CML (30), MDS/CMMoL
(7), AML (5), CLL (2), Myeloma (2), Severe Aplastic Anemia (1)
and ALL (1). Currently 38 patients are alive in complete remission,
4 alive with molecular recurrence of CML but 6 have died (2 of sec-
ond malignancy, one each of relapse, sepsis, CVA and multiorgan
failure). Health Related Quality of Life (HRQOL) analysis using
the the SF-36 scale found no significant difference in physical or
mental health between long term survivors overall and the U.S. gen-
eral population. Nevertheless, a subset of survivors reporting symp-
tom distress had lower HRQOL. Since immune dysfunction
underlies many late effect complications, we analyzed immune re-
constitution. Quantitative immunoglobulins for survivors were in
the normal range for the population as were absolute lymphocyte
counts (ALC), total CD31, CD31CD41, CD31CD81, CD191
and NK cells. Samples from 15 long term survivors were then com-
pared to current samples from their sibling donors and no quantita-
tive differences were observed in absolute lymphocyte counts (ALC),
total CD31, CD31CD41, CD31CD81, CD191 and NK cells.
However there was a significant expansion in the Treg (CD251/
CD41/FoxP31) compartment (p5 0.02), accompanied by a decline
in naive T cells (CD45RA1/CD271) (p\0.003) and recent thymic
emigrants (TREC1) (p\0.05) in survvors compared to their sibling
donors. T cell receptor repertoire analysis showed that there was no
significant difference in total complexity score of TCR-Vb diversity
between the patients and their donors, although TCR-Vb subfamily
spectratyping profiles showed divergence between patients and do-
nors with both gain and loss of clonotypes. In conclusion, survivors
in their second decade tend to remain vulnerable with disproportion-
ate mortality from diverse causes. Their QOL is typically excellent
but a small subset do experience persistent symptom distress. Im-
mune parameters, even 10 years postHSCT, are not completely nor-
mal and reflect impaired thymopoiesis and repertoire divergence.229
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Chronic graft-versus-host disease (GVHD) threatens patient-re-
ported quality of life (QOL) after allogeneic hematopoietic cell
transplantation. However, the sensitivity of serially assessed chronic
GVHD severity to change inQOL has not been determined.We ex-
amined the sensitivity of changes in chronic GVHD severity (deter-
mined separately by NIH consensus severity criteria, physician-
assessed severity, and patient-reported chronic GVHD severity) to
changes inQOL asmeasured with the SF-36 and FACT instrumentsS238in a prospectively assembled multi-center cohort of chronic GVHD
affected HCT recipients. A total of 341 individual adult (median age
52, range 19 – 79) patients (182 incident, 159 prevalent) from 6
transplant centers contributed data to an analysis encompassing
917 total visits. Chronic GVHD involvement most commonly in-
cluded skin (56%), oral (53%), ocular (55%), and hepatic (39%)
manifestations. On follow up, the majority had unchanged chronic
GVHD severity. However, follow up visits demonstrated improve-
ment (NIH 16%, physician 20%, patient 22%), or rather worsening
(NIH 17%, physician 14%, patient 16%) in others. Subjects with
complete or with missing data had similar clinical characteristics, ex-
cepting that those without missing data were more likely to have
a college or post-graduate degree (p 5 0.007). Univariable analysis
accounting for repeated observations was performed to examine
the relationship between change in chronic GVHD severity and
change in QOL. Multivariable analysis was performed considering
patient socio-demographic, disease, and transplantation covariates.
Conclusions discerned in univariable analysis persisted: Change in
NIH severity was not sensitive to change in QOL. Change in physi-
cian-assessed severity was sensitive to changes in SF-36 MCS (men-
tal component summary), and FACT-TOI (trial outcome index),
FACT-Total, and FACT-BMT (BMT subscale). Change in pa-
tient-reported severity was sensitive to changes in all QOL outcomes
(p\ 0.001 for each). These data demonstrate that NIH and physi-
cian determined chronic GVHD severity assessment do not capture
the full symptomburden experienced by chronicGVHDaffected pa-
tients. The data support the incorporation of patient-reported
chronic GVHD severity in the evaluation of severity change and
therapeutic response in the conduct of clinical trials as well as routine
clinical practice for those affected by chronic GVHD.230
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Introduction: Squamous cell carcinoma (SCC) of the oral cavity or
esophagus is a common secondary cancer after allogeneic hemato-
poietic stem cell transplantation (allo-HCT). As different from
oral SCC, diagnosis of esophageal carcinoma upon clinical symp-
toms is relatively late and mostly fatal. Thus, early detection of
esophageal carcinoma is highly desired. Previous studies reported
that human papillomavirus (HPV) infection is correlated with devel-
oping oral SCC after HCT. HPV infection is well documented as
a causative organism of cervical or oral SCC. Besides, several studies
have shown that the expression of p16 in biopsy specimens is associ-
ated withHPV infection in cervical SCC and is also found in precan-
cerous states such as intraepithelial neoplasia, dysplasia and
koilocytic change. In the gynecology field, p16 staining is commonly
used for biomarkers of HPV infection.
Purpose and Methods: To clarify the correlation between expres-
sion of p16 and the development of esophageal carcinoma after
allo-HCT, 48 patients who survived for at least 1 year after HCT
were enrolled in this study. They were examined by endoscopy and
Lugol staining. If Lugol’s voiding lesion was found, biopsy and the
staining for p16 were performed.
Result: The median age was 45 years, and the median duration of
follow-up was 7.3 years. In one patient, a tumor found by endoscopy
was diagnosed as SCC. Of the remaining 47 patients who received
Lugol staining, 22 showed unstained areas and were examined by bi-
opsy. Expression of p16 was found in 15 of the 22 patients. Among
fifteen p16- positive patients, precancerous lesions such as intraepi-
thelial neoplasia (n 5 1), dysplasia (n 5 1) and koilocytic changes (n
5 5) were found. On the other hand, among seven p16-negative pa-
tients, only a koilocytic change was found in one patient. Chronic
GVHD and administration of immunosuppressin at the examination
were significantly related with p16 positivity.
Poster Session I S239Conclusion: The present study demonstrates that examination by
endoscopy and Lugol staining is a useful tool to detect precancerous
esophageal carcinoma. Although the direct correlation between ex-
pression of p16 and HPV infection in this study is still under study,
it suggests that HPV may be a causative pathogen of esophageal
carcinoma after allo-HCT under immunosuppressive conditions
after allo-HCT.231
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Non-infectious lung injury (NILI) after allogeneic (allo) hemato-
poetic stem cell transplantation (HSCT) significantly contributes to
morbidity and mortality and can manifest as restrictive or/and ob-
structive pulmonary function impairment. Beneficial effects of mac-
rolides on airway inflammation and pulmonary obstruction both
after allo-HSCT and solid organ transplantation (SOT) have been
described in clinical studies.We tested the role of long-term azithro-
mycin (Azi) administration in reducing the severity of NILI follow-
ing murine HSCT. Lethally (12Gy) irradiated B6D2F1 mice
received 5  10E6 bone marrow and 6  10E6 splenocytes from ei-
ther syngeneic (syn) (B6D2F1) or allo (C57BL/6) donors. One half
of allo recipients received drinking water supplemented with Azi
(1mg/ml between day 114 and day 117, 0.5mg/ml from day 118
until day1100), whereas the other half of allo and syn recipients re-
ceived water only. On day198, surviving animals were analyzed and
pulmonary function tests (PFT) were performed.
All syn animalswere alive andwithout clinical signs of graft-versus-
host disease. Azi treatment in allo recipients resulted in better overall
survival when compared to allo controls (53.3% vs. 29.4%), but did
not relate to changes in clinical weight loss, mobility, fur and skin
changes (score: 2.7 vs. 2.7). PFT, however, revealed significant
improvement in both restrictive and obstructive parameters for
Azi-treated animals when compared to allo controls (VC:
0.53460.069 vs. 0.43560.068 ml; p 5 0.034; Cchord: 0.02960.004
vs. 0.02160.002 ml/cm H2O; p 5 0.0049; FEV50: 0.44660.06 vs.
0.36960.039 ml; p 5 0.032). Moreover, Cchord and FEV50 were
not significantly different between AZI animals and syn controls.
Neutrophil countswere assessedbymyeloperoxidase (MPO) activity,
with Azi-treatment resulting in its reduction. Further, CXCL1 and
CXCL2 lung protein levels as well as IL-6 and TGFb1 levels were
significantly lower in the Azi allo group than in allo controls, whereas
no differences were seen for TNF, IFNg or CXCL9.
Our data experimentally confirm the beneficial effects of Azi on
pulmonary function impairment in allo-HSCT recipients as being
at least partially mediated through altered chemo- and cytokine ex-
pression and decreased neutrophil recruitment to the lung. They
strengthen the concept of Azi as a well-tolerated, inexpensive but
yet efficient drug in the treatment of NILI following allo-HSCT
and SOT.232
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Background: Pediatric bone marrow transplantation (BMT) for
various diseases can lead to endocrine system dysfunction due to
the common preparative regimens involving chemotherapy and
radiation therapy.
Objective: The primary objective of this study was to assess the
prevalence of post BMT endocrine complications in children treated
at the Alberta Children’s Hospital from 1991-2001. The secondary
objectives were to characterize the time of onset of endocrine dys-function, underlying disease processes, chemotherapy, radiation
therapy, and age at the time of BMT.
Methods: A retrospective cohort study design was used. Subjects
were included if they were less than 18 years of age at the time of their
BMT (allogeneic or autologous) at the Alberta Children’s Hospital,
the BMTwas performed between January 1, 1991 andDecember 31,
2001, the subject had follow-up through the Alberta Children’sHos-
pital for at least one year post BMT, and their charts were available
for review. Subjects were excluded if they had a pre-existing diagno-
sis of an endocrine condition under evaluation prior to their bone
marrow transplant.
Results:A total of 194 pediatric BMTprocedures were performed at
the Alberta Children’s Hospital from January 1, 1991 to December
31, 2002. Of these, 150 complete charts were available for review.
Sixty five subjects received follow up care at other centers and
were not included in this study. Therefore, a total of 85 subjects
were included in this review. The prevalences of endocrine compli-
cations identified were: primary hypothyroidism 1.2%, compensated
hypothyroidism 7.0%, hyperthyroidism 2.4%, hypergonadotrophic
hypogonadism 22.4%, abnormal bone density 2.4%, and secondary
diabetes mellitus 1.2%.
Conclusions: These findings emphasize the need to screen for en-
docrine system dysfunction, particularly hypergonadotrophic hypo-
gonadism in children who have undergone BMT. Children need to
be followed long term so that endocrine complications can be
diagnosed and treated promptly.233
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Practice variation in immune suppression (IS) liberation after allo-
geneic hematopoietic cell transplantation (HCT) is anticipated to
have important consequences, but has not been characterized to
date. We conducted a survey of transplant physician members of
the American Society for Blood andMarrow Transplantation to dis-
cern variation in IS management and attitudes toward this practice,
characterize the burden of GVHD in the setting of IS taper, and to
describe the proportion of HCT recipients who successfully liberate
from IS by 2 and 5 years. From 1,100 eligible physicians, 225 (21%)
completed the electronic survey. Practice varied according to re-
ported time of initiation of IS taper post-HCT, sequence of agents
tapered, frequency of changes, and strategy utilized; 25% reported
no consistent strategy. In the presence of post-HCT relapse, 71%
of respondents recommended stopping all IS agents, and 50% uti-
lized donor lymphocyte infusion. Confidence in therapeutic decision
making was limited:Most reported no consistent practice guidelines,
41% reported that their current IS liberation strategy is not ade-
quate, and 26% reported being either uncomfortable or very uncom-
fortable with making decisions on IS management. The majority
indicated that they could not predict who would develop GVHD
on taper of IS, and reported a resultant burden of GVHD emerging
or recurring in the setting of IS taper. In the setting of recurrent
GVHD following IS taper, therapeutic approaches differed: 44% re-
sumed the original IS agents; 73% started 1-2mg/kg of steroids; and
16% both started 1-2mg/kg steroids and added an additional sys-
temic IS agent. The potential adverse consequence of GVHD
emerging or recurring in the setting of IS taper was highlighted by
HCT physicians’ self-report of the proportion of these cases that
are not successfully treated to resolution. Projected rates of IS liber-
ation increased from 2 to 5 years post-HCT, and differed signifi-
cantly according to donor relation and stem cell source utilized
(p \ 0.05). The marked variation in practice, burden of GVHD
emerging in the setting of IS taper, and limited confidence in thera-
peutic decision making all highlight shortcomings in an essential
component of HCT physicians’ scope of practice. These findings
argue for both more rigorous study of IS liberation post-HCT and
development of evidence-based practice guidelines.
